First Severe Clostridioides difficile Episode: Paying More Now or Risking a Recurrence Later
A single hospitalized patient with a first severe episode of Clostridioides difficile infection, weighing fidaxomicin's lower recurrence rate against vancomycin's far lower cost and identical short-term cure rate.
Rosalind P., a 76-year-old widow, was admitted from the emergency department with twelve days of worsening diarrhea that started roughly a week after finishing a course of amoxicillin-clavulanate for a dental abscess — her first antibiotic exposure in over two years. Stool PCR confirmed Clostridioides difficile, and her labs meet severity criteria outright: WBC 17.2 and a creatinine 1.6 above her documented baseline of 0.9. This is her first C. difficile episode of any kind, no prior recurrence history to draw on, and she lives independently in her own apartment with weekly help from a home health aide, a routine she is anxious to get back to rather than transition into a skilled nursing stay.
First-episode severe C. difficile has a real choice built into it now that didn't used to exist: fidaxomicin and oral vancomycin cure the acute episode at essentially the same rate, but head-to-head trials comparing the two have consistently found a meaningfully lower recurrence rate with fidaxomicin, a difference substantial enough that IDSA and SHEA guidelines now name fidaxomicin as the preferred first-line agent for an initial episode. What that preference doesn't resolve on its own is cost: a full fidaxomicin course typically runs many times the price of the same course of oral vancomycin, a gap significant enough that some hospital formularies and insurers still require vancomycin be tried first or restrict fidaxomicin to documented recurrent disease. Rosalind's own profile carries real recurrence risk factors of the kind the recurrence-prevention literature flags — her age, the severity of this first episode, and a return to independent living without the close daily supervision an inpatient or skilled-nursing setting would provide if early symptoms recurred quietly at home. None of that resolves the cost question on its own — a recurrence-risk profile doesn't change what either drug costs — but it does change what a recurrence would actually mean for her specifically: not a phone call from a supervised facility catching it early, but a woman living alone noticing something is wrong only once it's already progressed.
Hospital day 1, choosing the initial regimen
I'd start fidaxomicin. Both drugs cure the current episode at essentially the same rate, but the head-to-head trials consistently show a meaningfully lower recurrence rate with fidaxomicin, which is exactly why IDSA and SHEA guidelines now name it preferred first-line for an initial episode. Rosalind's own profile — her age, a severe first episode, returning to independent living without daily supervision — is close to the kind of patient that recurrence advantage matters most for.
I don't disagree with the guideline data, but I want the cost difference on the table honestly. A fidaxomicin course typically runs several times what the same course of oral vancomycin costs, and the two drugs are a dead heat on curing this actual episode — the entire case for fidaxomicin is a probabilistic future benefit, not better treatment of what's happening right now. For a patient without elevated recurrence risk, I think vancomycin remains entirely defensible.
I'm not arguing against fidaxomicin categorically — I'm arguing the guideline preference is an average recommendation, and averages aren't the same thing as what's right for every individual patient sitting in front of us.
The hospitalist's framing is actually the right test to apply, not a reason to default to vancomycin — the question is whether Rosalind specifically sits in the group fidaxomicin's recurrence advantage matters most for, and she does. Age 65 and older, a severe index episode, and a discharge plan back to independent living without close daily monitoring are recognized recurrence-risk factors, not incidental details — a quiet early recurrence at home, caught late, is a materially worse outcome for her than it would be for a younger patient with close support already in place. The cost differential is real, but weighed against her specific risk profile rather than treated as a blanket objection, fidaxomicin is the better fit here.
Agreed: fidaxomicin 200mg twice daily for 10 days, with an explicit note in the discharge plan that the choice was risk-factor-driven, not a blanket guideline default, so a future lower-risk patient isn't automatically treated the same way without that reasoning being reapplied. The hospitalist's cost concern is documented as a standing consideration for the next patient this comes up for, not overruled as invalid — just outweighed by Rosalind's specific profile this time.